Bluefin Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Bluefin Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,000	Closed	-$347K	–	329
2023 Q3	$347K	Sell	3,000 -54,577	-95%	-$5.86M	0.03%	77
2023 Q2	$5.92M	Buy	+57,577	New	+$6.07M	1.13%	16
2017 Q1	–	Sell	-33,956	Closed	-$549K	–	699
2016 Q4	$549K	Buy	+33,956	New	+$616K	0.03%	211

Other funds holding HZNP

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Bluefin Capital Management's HZNP Position: Q4 2023 in Review

Bluefin Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 3,000 shares — an estimated $347K sold.

Bluefin Capital Management first reported a position in HZNP in Q4 2016 and held it in 3 quarters. The position peaked at $5.92M in Q2 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Bluefin Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Bluefin Capital Management sold 3,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $347K.
Bluefin Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2016 and held it in 3 quarters.
Bluefin Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $5.92M in Q2 2023.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Bluefin Capital Management's 13F filing for Q4 2023, filed 16 Feb 2024.